<unk>  was approved by the U.S. Food and Drug Administration (FDA) in March 2011, to treat people with late-stage melanoma that has spread or cannot be removed by surgery. It was later approved by the US FDA on October 28, 2015, for stage 3 patients as adjuvant therapy. On February 1, 2012, Health Canada approved<unk>  for "treatment of unresectable or metastatic melanoma in patients who have failed or do not tolerate other systemic therapy for advanced disease."<unk>  was approved in the European Union (EU), for second line treatment of metastatic melanoma in November 2012. Nivolumab, in combination with<unk>  is indicated for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma.<unk> , in combination with nivolumab, is indicated for the treatment of adults and adolescents twelve years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.<unk> , in combination with nivolumab, is indicated for the treatment of people with hepatocellular carcinoma who have been previously treated with sorafenib.<unk> , in combination with nivolumab, is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test. In October 2020, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab with<unk>  for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery. This is the first drug regimen approved for mesothelioma in sixteen years and the second FDA-approved systemic therapy for mesothelioma.
Ipilimumab
Pembrolizumab
Daratumumab
Axitinib
Teprotumumab
Siltuximab
Blinatumomab
Ofatumumab